{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:42:38Z","timestamp":1790347358091,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this review is to report, characterize, and map the strategies used to implement vancomycin therapeutic drug monitoring using the area under the curve\/minimum inhibitory concentration (AUC\/MIC) ratio or vancomycin model-informed precision dosing (MIPD) in the hospital setting. Barriers to and facilitators of implementation will also be included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Implementation of both vancomycin AUC\/MIC-based therapeutic drug monitoring and vancomycin MIPD will continue to remain challenging until health care providers have the necessary suite of implementation tools to overcome many of the contextual barriers they currently face. To expedite the delays to implementation, a scoping review will be a useful preliminary step to collate, summarize, and present the relevant and published literature on this topic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria:<\/jats:title>\n                    <jats:p>\n                      The proposed scoping review will consider studies describing methods or strategies that include health care workers involved in the implementation of vancomycin AUC\/MIC-based therapeutic drug monitoring or vancomycin MIPD for methicillin-resistant\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      infections. Studies that examine barriers and facilitators to implementation will also be included.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This review will be conducted using JBI methodology and reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) checklist. The search strategy will include 3 databases: MEDLINE (Ovid), Embase (Ovid), and Scopus. MedNar and ProQuest Dissertations and Theses will be searched for gray literature. Two reviewers will independently screen titles and abstracts and full-text documents, and conduct data extraction. Data from included studies will be extracted using a standardized template, and findings will be summarized narratively and accompanied by tables and figures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Review registration:<\/jats:title>\n                    <jats:p>OSF https:\/\/osf.io\/pfsnh\/<\/jats:p>\n                  <\/jats:sec>","DOI":"10.11124\/jbies-24-00250","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:14:22Z","timestamp":1765275262000},"page":"571-579","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Implementation of vancomycin area under the curve therapeutic drug monitoring with model-informed precision dosing: a scoping review protocol"],"prefix":"10.11124","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-2900","authenticated-orcid":false,"given":"Brett","family":"Ritchie","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-7287","authenticated-orcid":false,"given":"Stephanie E.","family":"Reuter","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5975-4179","authenticated-orcid":false,"given":"Kylie","family":"Porritt","sequence":"additional","affiliation":[{"name":"JBI, School of Public Health, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"1","key":"R1-20260317","doi-asserted-by":"crossref","first-page":"ofae002","DOI":"10.1093\/ofid\/ofae002","article-title":"Model-informed precision dosing improves outcomes in patients receiving vancomycin for gram-positive infections","volume":"11","author":"Hall","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"R2-20260317","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jinf.2022.06.029","article-title":"Assessment of an institutional guideline for vancomycin dosing and identification of predictive factors associated with dose and drug trough levels","volume":"85","author":"Gu","year":"2022","journal-title":"J Infect"},{"issue":"3","key":"R3-20260317","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/FTD.0000000000000500","article-title":"Vancomycin area under the curve simplified","volume":"40","author":"Lewis","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"1","key":"R4-20260317","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"R5-20260317","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R6-20260317","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FTD.0000000000000944","article-title":"Optimal practice for vancomycin therapeutic drug monitoring: position statement from the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"44","author":"Reuter","year":"2022","journal-title":"Ther Drug Monit"},{"issue":"6","key":"R7-20260317","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/08971900211012395","article-title":"Assessment of the implementation of AUC dosing and monitoring practices with vancomycin at hospitals across the United States","volume":"35","author":"Bradley","year":"2022","journal-title":"J Pharm Pract"},{"issue":"3","key":"R8-20260317","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4212\/cjhp.3337","article-title":"Vancomycin therapeutic drug monitoring: a cross-sectional survey of Canadian hospitals","volume":"76","author":"Jorgensen","year":"2023","journal-title":"Can J Hosp Pharm"},{"key":"R9-20260317","doi-asserted-by":"crossref","first-page":"1370040","DOI":"10.3389\/fphar.2024.1370040","article-title":"Is it time to recommend AUC-based vancomycin therapeutic drug monitoring only? A cross-sectional survey in China","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"R10-20260317","article-title":"Barriers and strategies in guideline implementation-a scoping review","volume":"4","author":"Fischer","year":"2016","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"R11-20260317","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12913-018-3671-z","article-title":"\u201cThere is nothing so practical as a good theory\u201d: a pragmatic guide for selecting theoretical approaches for implementation projects","volume":"18","author":"Lynch","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"R12-20260317","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/cid\/ciz1011","article-title":"Putting the dissemination and implementation in infectious diseases","volume":"71","author":"Burnham","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R13-20260317","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/jep.12741","article-title":"The struggle of translating science into action: foundational concepts of implementation science","volume":"24","author":"Rapport","year":"2018","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"R14-20260317","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13012-017-0656-y","article-title":"Criteria for selecting implementation science theories and frameworks: results from an international survey","volume":"12","author":"Birken","year":"2017","journal-title":"Implement Sci"},{"key":"R15-20260317","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"R16-20260317","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.2147\/IDR.S176519","article-title":"Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review with meta-analysis","volume":"11","author":"Phillips","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"1","key":"R17-20260317","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11096-024-01822-x","article-title":"Model-informed precision dosing of vancomycin in clinical practice: an intervention development study","volume":"47","author":"Swartling","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"R18-20260317","doi-asserted-by":"crossref","first-page":"n2061","DOI":"10.1136\/bmj.n2061","article-title":"A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance","volume":"374","author":"Skivington","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"R19-20260317","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13012-020-01041-8","article-title":"The Implementation Research Logic Model: a method for planning, executing, reporting, and synthesizing implementation projects","volume":"15","author":"Smith","year":"2020","journal-title":"Implement Sci"},{"issue":"1","key":"R20-20260317","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/08971900211027271","article-title":"Doing more with less: pragmatic implementation of vancomycin area-under-the-curve (AUC) monitoring","volume":"36","author":"Huang","year":"2023","journal-title":"J Pharm Pract"},{"issue":"1","key":"R21-20260317","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s12913-022-07927-1","article-title":"Would they accept it? An interview study to identify barriers and facilitators to user acceptance of a prescribing advice service","volume":"22","author":"Yager","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"R22-20260317","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/bcp.14496","article-title":"Would they trust it? An exploration of psychosocial and environmental factors affecting prescriber acceptance of computerised dose-recommendation software","volume":"87","author":"Carland","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"R23-20260317","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13012-024-01352-0","article-title":"Navigating the field of implementation science towards maturity: challenges and opportunities","volume":"19","author":"Chambers","year":"2024","journal-title":"Implement Sci"},{"issue":"12","key":"R24-20260317","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/ajhp\/zxz070","article-title":"Readiness to implement vancomycin monitoring based on area under the concentration-time curve: a cross-sectional survey of a national health consortium","volume":"76","author":"Kufel","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"R25-20260317","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1111\/bcp.14834","article-title":"Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices","volume":"87","author":"Carland","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"R26-20260317","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"R28-20260317","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"R29-20260317","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"R30-20260317","doi-asserted-by":"crossref","first-page":"520","DOI":"10.11124\/JBIES-22-00123","article-title":"Recommendations for the extraction, analysis, and presentation of results in scoping reviews","volume":"21","author":"Pollock","year":"2023","journal-title":"JBI Evid Synth"}],"container-title":["JBI Evidence Synthesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-24-00250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:35:59Z","timestamp":1786451759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-24-00250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.11124\/jbies-24-00250","relation":{},"ISSN":["2689-8381"],"issn-type":[{"value":"2689-8381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}